[HTML][HTML] Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the …
T Treasure, L Lang-Lazdunski, D Waller… - The lancet …, 2011 - thelancet.com
Background The effects of extra-pleural pneumonectomy (EPP) on survival and quality of life
in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed …
in patients with malignant pleural mesothelioma have, to our knowledge, not been assessed …
[HTML][HTML] Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
DA Fennell, S Ewings, C Ottensmeier… - The Lancet …, 2021 - thelancet.com
Background No phase 3 trial has yet shown improved survival for patients with pleural or
peritoneal malignant mesothelioma who have progressed following platinum-based …
peritoneal malignant mesothelioma who have progressed following platinum-based …
[HTML][HTML] Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
MF Muers, RJ Stephens, P Fisher, L Darlison… - The Lancet, 2008 - thelancet.com
Background Malignant pleural mesothelioma is almost always fatal, and few treatment
options are available. Although active symptom control (ASC) has been recommended for …
options are available. Although active symptom control (ASC) has been recommended for …
[HTML][HTML] British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma
I Woolhouse, L Bishop, L Darlison, D De Fonseka… - Thorax, 2018 - thorax.bmj.com
Refer all patients with a chest X-ray suggestive of MPM urgently (via the 2-week wait
suspected cancer pathway in England and Wales). Consider referral for further investigation …
suspected cancer pathway in England and Wales). Consider referral for further investigation …
Understanding the palliative care needs and experiences of people with mesothelioma and their family carers: An integrative systematic review
M Harrison, C Gardiner, B Taylor… - Palliative …, 2021 - journals.sagepub.com
Background: People with mesothelioma and their families have palliative care needs
throughout the relatively short trajectory of their illness. Aim: To describe the palliative care …
throughout the relatively short trajectory of their illness. Aim: To describe the palliative care …
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial
DA Fennell, A King, S Mohammed… - The Lancet …, 2021 - thelancet.com
Background Malignant mesothelioma remains an incurable cancer, with no effective
treatments in the setting of relapsed disease. Homologous recombination deficiency predicts …
treatments in the setting of relapsed disease. Homologous recombination deficiency predicts …
Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) …
E Lim, L Darlison, J Edwards, D Elliott, DA Fennell… - BMJ open, 2020 - bmjopen.bmj.com
Introduction Mesothelioma remains a lethal cancer. To date, systemic therapy with
pemetrexed and a platinum drug remains the only licensed standard of care. As the median …
pemetrexed and a platinum drug remains the only licensed standard of care. As the median …
Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial
N Bayman, W Appel, L Ashcroft… - Journal of Clinical …, 2019 - eprints.whiterose.ac.uk
PURPOSE Prophylactic irradiation to the chest wall after diagnostic or therapeutic
procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread …
procedures in patients with malignant pleural mesothelioma (MPM) has been a widespread …
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
8507 Background: All patients with malignant pleural mesothelioma (MPM) eventually
relapse following standard chemotherapy. However, there is no standard treatment option in …
relapse following standard chemotherapy. However, there is no standard treatment option in …
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial
DA Fennell, A King, S Mohammed, A Greystoke… - The Lancet …, 2022 - thelancet.com
Background Genetically stratified therapy for malignant mesothelioma is unavailable.
Mesotheliomas frequently harbour loss of the chromosome 9p21. 3 locus (CDKN2A–MTAP) …
Mesotheliomas frequently harbour loss of the chromosome 9p21. 3 locus (CDKN2A–MTAP) …